The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Natalizumab effects on immune cell responses in multiple sclerosis
Abstract
Objective: Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients. Methods: Blood was obtained before and after serial monthly natalizumab infusions to track functional expression of VLA‐4 and migratory capacity of immune cells. The impact of infusion on activation thresholds of immune cells was evaluated. Results: Preinfusion VLA‐4 expression differed across immune cell subsets. Natalizumab significantly, albeit partially, diminished VLA‐4 expression on circulating immune cells. Cell subsets were differentially affected. Treatment significantly decreased migratory capacity of immune cells, correlating well with changes in VLA‐4 expression. Effects of a single dose were not saturating and did not persist through the monthly dose interval. Infusion effect varied across patients but was remarkably stable in individual patients, over multiple infusions. Treatment significantly modulated proliferative responses of immune cells. Interpretation: To our knowledge, we provide first proof of concept that natalizumab diminishes migratory capacity of immune cells. Our prospective study further shows that effects of therapy likely (1) differ for distinct immune cell subsets, (2) are not sustained over current dose interval, (3) have unique profiles in individual patients, and (4) include modulation of activation threshold of immune cells. Monitoring these parameters could be relevant to ongoing safety and efficacy considerations. Ann Neurol 2006;59:748–754
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Determinants of Human B Cell Migration Across Brain Endothelial Cells
Alter, A., Duddy, M., Hebert, S., Biernacki, K., Prat, A., Antel, J. P., Yong, V. W., Nuttall, R. K., Pennington, C. J., Edwards, D. R., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4497 · Cited by 195
Self-citation
Cited by
Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., & Fedyk, E. R. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153973 · Cited by 456
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Self-citationB cells and multiple sclerosis
Franciotta, D., Salvetti, M., Lolli, F., Serafini, B., & Aloisi, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70192-3 · Cited by 287
Stüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1383 · Cited by 271
Self-citationStüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00003.x · Cited by 123
Metadata
- Authors
- Niino, M., Bodner, C., Simard, M., Alatab, S., Gano, D., Kim, H. J., Trigueiro, M., Racicot, D., Guérette, C., Antel, J. P., Fournier, A., Grand'Maison, F., & Bar‐Or, A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-04-21
- Volume
- 59
- Issue
- 5
- Pages
- 748-754
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2057903396
- Cited by
- 210
- References
- 2
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.